Fig. 3

Therapeutic effects of combination of EZH2 and BRAF inhibition in vitro. Four BRAF mutated cell lines (A375, SK-MEL-5, A2058, WM 115) was treated with indicated concentrations of inhibitors for 48 h. The proliferation of cells was evaluated by Cell Tilter method. a, b Inhibitory effect of monotherapy with vemurafenib and GSK126 respectively. c–f Comparison of inhibitory effect of the combined treatment with vemurafenib and GSK126 and single agent alone in A2058, SK-MEL-5, A375 and WM 115 cell growth. g–j The calculated CI (Combination Index) of combination therapy in A2058, SK-MEL-5, A375 and WM 115 cell lines. The results were presented as mean ± SD of three independent experiments. The statistical significance of the growth curves was evaluated by Mauchly’s test of sphericity (*P < 0.05; **P < 0.01; ***P < 0.001)